Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome.
Christoph C KaufmannMarie MuthspielLaura LunzerEdita PogranDavid ZweikerAchim Leo BurgerJohann WojtaKurt HuberPublished in: Journal of clinical medicine (2024)
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y 12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios.
Keyphrases
- acute coronary syndrome
- antiplatelet therapy
- percutaneous coronary intervention
- atrial fibrillation
- clinical trial
- risk factors
- emergency department
- end stage renal disease
- ejection fraction
- climate change
- newly diagnosed
- randomized controlled trial
- type diabetes
- combination therapy
- skeletal muscle
- single cell
- subarachnoid hemorrhage
- smoking cessation
- machine learning
- insulin resistance
- quantum dots
- deep learning
- phase ii
- oxidative stress
- sensitive detection